Earnings Feed
Start Free
ADMA BIOLOGICS, INC.·4

Feb 17, 9:39 PM ET

Grossman Adam S 4

4 · ADMA BIOLOGICS, INC. · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated

ADMA BIOLOGICS (ADMA) CEO Adam Grossman Sells Shares After Option Exercise

What Happened
Adam S. Grossman, President, CEO and Director of ADMA Biologics (ADMA), exercised options to acquire 15,000 shares at $5.40 per share (cost $81,000) on February 17, 2026, and sold a total of 21,000 shares in open market transactions that day at $16.08 per share (proceeds $337,680). The filing also reports a derivative disposition of 15,000 with a reported price of $0.00 (reported as a derivative transaction). The sales were executed under a Rule 10b5‑1 trading plan.

Key Details

  • Transaction date: February 17, 2026.
  • Exercise: 15,000 shares acquired at $5.40 each = $81,000 (code M).
  • Sales: 15,000 shares sold @ $16.08 = $241,200; 6,000 shares sold @ $16.08 = $96,480; total sale proceeds = $337,680 (code S).
  • Derivative disposition: 15,000 reported at $0.00 (code M) — reported separately in the filing.
  • Plan: Sales were effected pursuant to a Rule 10b5‑1 trading plan entered Nov 14, 2025 (footnote F1).
  • Holdings noted in footnotes: the filing lists 969,684 shares of common stock owned by Grossman and substantial unvested RSUs (about 1,314,695 unvested RSUs across multiple grants per F3–F5). An option grant from Feb 26, 2024 (underlying ~870,948 shares, with 217,737 vested on Feb 26, 2025) is described in footnote F8.
  • Filing timing: filed on Feb 17, 2026 (no late filing indicated in this record).

Context

  • This filing shows an options exercise and same‑day open‑market sales — a common pattern where exercised shares are sold (often to cover exercise cost/taxes or to monetize gains). The presence of a 10b5‑1 plan indicates the sales were preplanned.
  • Derivative transactions reported at $0.00 typically reflect option/derivative-related dispositions reported separately on Form 4; the filing itself provides the official record but does not disclose management’s motives.

Insider Transaction Report

Form 4
Period: 2026-02-17
ADMA BIOLOGICS, INC.ADMA
Grossman Adam S
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-17$5.40/sh+15,000$81,000→ 2,305,379 total
  • Sale

    Common Stock

    [F1][F2]
    2026-02-17$16.08/sh−15,000$241,200→ 2,290,379 total
  • Sale

    Common Stock

    [F1][F2][F3][F4][F5]
    2026-02-17$16.08/sh−6,000$96,480→ 2,284,379 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F8]
    2026-02-17−15,000→ 705,950 total
    Exercise: $5.40Exp: 2034-02-26→ Common Stock (15,000 underlying)
Holdings

  • Common Stock

    [F6]
    (indirect: See Footnote)
    1,143,426

  • Common Stock

    [F7]
    (indirect: See Footnote)
    580,957
Footnotes (8)
  • [F1]Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  • [F2]The price reported in Column 4 is the price at which the shares were sold.
  • [F3]Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F4](continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  • [F5](continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  • [F6]These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  • [F7]These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  • [F8]The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Signature
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact|2026-02-17

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4